Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
118 points by _Microft
Moderna and Merck announced that their mRNA cancer vaccine has been shown to reduce death and recurrence rates by 42% in clinical trials. This follows earlier reports confirming the trial’s success, indicating significant progress in cancer treatment using mRNA technology.